Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

3.710 +0.140 (+3.92%)
Streaming Delayed Price Updated: 12:17 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
News headline image
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop ↗
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug... 
Via Benzinga
News headline image
ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study ↗
ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated... 
Via Benzinga
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,... 
Via FinancialNewsMedia
Topics Law Enforcement
News headline image
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
News headline image
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
News headline image
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
News headline image
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders ↗
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
News headline image
Atai Life Launches Depression-Focused Firm ↗
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. ... 
Via Benzinga
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
The Week In Psychedelics 
Via Benzinga
News headline image
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery ↗
Photo by CDC on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its... 
Via Benzinga
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
News headline image
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗
The Week In Psychedelics: 
Via Benzinga
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing... 
Via FinancialNewsMedia
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
Via FinancialNewsMedia
News headline image
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out ↗
DemeRx IB, Inc., a company developing psychedelic ibogaine for the treatment of opioid use disorder, has begun a phase 1/2... 
Via Benzinga
News headline image
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Via FinancialNewsMedia
News headline image
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine ↗
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsid... 
Via Benzinga
News headline image
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗
Last Week In Psychedelics: 
Via Benzinga
News headline image
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
News headline image
Psychedelic Drug Industry Report Card For 2021 ↗
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
News headline image
What 10 Analyst Ratings Have To Say About ATAI Life Sciences ↗
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.